NSCLC, metastatic 1


Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC. Final analysis of the multicenter, randomized, phase III BEVERLY trial

M.C. Piccirillo, et al.


The addition of BEV to E significantly prolonged IA-PFS compared with E alone as first-line treatment in Italian EGFR-mutated NSCLC patients, with no unexpected safety issues. Blinded radiologic revision of PFS and ORR is ongoing and will be presented at the meeting.




Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFR mutations; WJOG9717L study

Kenmotsu, et al.


This study failed to show the efficacy of OB arm for improving PFS in untreated pts with EGFR mutated Ns-NSCLC.




Primary Data from DESTINY-Lung01: A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Mutated (HER2m) Metastatic Non–Small Cell Lung Cancer (NSCLC)

B.T. Li, et al.


T-DXd demonstrated robust and durable activity in pts with previously treated HER2m NSCLC, with a manageable safety profile consistent with previous studies. This study provides compelling evidence of positive benefit/risk balance for T-DXd and supports its establishment as a potential new treatment standard for this population.



Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

B.T. Li and Others



Efficacy and Safety of Poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational Phase 2 study (ZENITH20-4)

Cornelissen, et al.


Poziotinib demonstrated clinically meaningful efficacy in newly diagnosed NSCLC patients with HER2 exon 20 mutations with 16 mg QD dosing. Safety profile was similar to other second generation TKIs with manageable AEs. Study is ongoing with BID dosing currently.




1254P - Efficacy and safety of tepotinib in patients (pts) with advanced age: VISION subgroup analysis of pts with MET exon 14 (METex14) skipping NSCLC

M.C.C. Garassino, E. Felip, H. Sakai, et al.

Conclusions: Tepotinib demonstrated robust and durable efficacy in elderly pts, with a manageable safety profile, and a low proportion of TRAEs leading to discontinuation. Given the vulnerability of pts of advanced age, prioritization of effective and convenient targeted therapies in this population is warranted.


Published also at the WCLC 2021:

Tepotinib in patients with MET exon 14 skipping NSCLC as identified by liquid or tissue biopsy

Enriqueta Felip, Marina Chiara Garassino, Hiroshi Sakai, et al.